银屑病生物制剂治疗对HIV阳性个体HIV病毒载量和CD4+细胞计数的影响:一项真实世界队列研究
这项在澳大利亚悉尼三级转诊中心开展的回顾性队列研究纳入36例接受生物制剂治疗的HIV阳性银屑病患者,与144例年龄、性别和HAART匹配的无银屑病HIV个体比较。结果显示,在HIV控制良好的个体中,生物制剂治疗银屑病12个月内未显著影响HIV病毒载量、CD4+细胞计数、CD4+比例和感染率。
要点
- HIV阳性银屑病患者接受生物制剂治疗12个月,HIV病毒载量和CD4+计数无显著变化。
- 按生物制剂类型分层分析,上述参数均无显著变化。
- 生物制剂组与对照组感染率和不良事件发生率无显著差异。
核心结论
- 在HIV控制良好的个体中,使用生物制剂治疗银屑病在治疗前12个月内未显著影响HIV病毒载量、CD4+细胞计数、CD4+比例和感染率。
研究设计与样本
- 回顾性队列研究,在澳大利亚悉尼一家三级转诊中心开展,纳入36例接受生物制剂治疗的HIV阳性银屑病患者,与144例年龄、性别和HAART匹配的无银屑病HIV个体比较,纳入时间为2010年至2022年。
主要发现
- 有银屑病与无银屑病个体之间的基线HIV病毒载量和CD4+计数无统计学显著差异。
- 无银屑病的HIV队列在12个月分析期内CD4+计数和HIV病毒载量无显著变化。
- 接受生物制剂治疗银屑病的HIV队列在12个月观察期内HIV病毒载量和CD4+计数亦无显著变化。
- 按所用生物制剂类型分层未发现这些参数有任何显著变化。
- 两队列间感染率和不良事件发生率无显著差异。
临床怎么用
- 原文结论指出,在HIV控制良好的个体中,生物制剂治疗银屑病在治疗前12个月内未显著影响HIV病毒载量、CD4+细胞计数、CD4+比例和感染率。
- 原文指出,生物制剂队列中观察到的轻微波动可能是未来病毒学失败的风险因素,需要未来前瞻性纵向研究。
局限性
- 原文指出,生物制剂队列中观察到的轻微波动可能是未来病毒学失败的风险因素,需要未来前瞻性纵向研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory disorder that also occurs in the setting of human immunodeficiency virus (HIV). Biological therapy has transformed the treatment landscape for psoriasis; however, individuals with HIV are excluded from clinical trials. The impact of biological therapy on blood parameters in HIV is unclear and is only observed in small case series. OBJECTIVE: The aim of this study was to assess the effect of biological therapy in psoriasis vulgaris in individuals with well-controlled HIV on CD4+ cell counts, CD4+ proportion and HIV viral load over 12 months. METHODS: This retrospective cohort study was conducted at a tertiary referral centre in Sydney, Australia and included 36 HIV-positive individuals with psoriasis treated with biological therapy, compared with 144 age-, gender- and HAART-matched individuals without psoriasis seen between 2010 and 2022. Outcomes of interest included HIV viral load, CD4+ cell count and incidence of infections. RESULTS: No statistically significant difference was seen in baseline HIV viral load and CD4+ count between individuals with and without psoriasis. No significant change in CD4+ count or HIV viral load was seen over the 12-month period of analysis in the HIV cohort without psoriasis. The HIV cohort treated with biological therapy for psoriasis also did not demonstrate any significant change in HIV viral load and CD4+ counts over the 12-month period examined. Stratification by type of biological therapy used did not identify any significant changes in these parameters. Rates of infections and adverse events were also not significantly different between cohorts. It is possible that minor blips seen in the biologics cohort may be a risk factor for future virological failure, and future prospective longitudinal studies are required. CONCLUSIONS: In individuals with well-controlled HIV, the use of biological therapy for psoriasis does not significantly impact HIV viral load, CD4+ cell count, CD4+ proportion and rates of infection over the first 12 months of therapy.
引用
- Xu J, Gill K, Flora A, et al. The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV-positive individuals: A real-world cohort study. J Eur Acad Dermatol Venereol. 2023. PMID: 36897246. doi:10.1111/jdv.19020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。